Dendritic cell vaccines

Medigene’s new generation of dendritic cell (DC) vaccines have optimal functional potential to activate potent immune responses

Medigene has established a DC vaccine platform for the generation of antigen-tailored DC vaccines prepared from patients’ own blood cells.

The patient-specific DCs produced by Medigene are derived from blood monocytes which are isolated and matured using a proprietary process which enables these autologous DCs to be produced rapidly in just a few days. Medigene’s DC vaccine production processes them in such a way that they can activate T cells as well as natural killer cells to attack the tumor. DCs are versatile in the forms of antigen they can use to initiate specific immune responses. DCs can be loaded with various tumor antigens to treat different forms of cancer. Since an immune response builds up over the total time of administration of the DC vaccine, this form of therapy is thought to be particularly suited for patients whose tumor burden has been reduced to such an extent (by chemotherapy or other means) that the prevention of the recurrence of the tumor disease is the main goal.

Medigene’s DC vaccine platform offers unique advantages:

  • Young and potent DCs can be manufactured in just three to five days.
  • High quantity yields of DC vaccines for up to two years or longer.
  • Cells stored frozen and administered through simple injections under the skin.
  • Potential to incorporate certain antigens to tailor DC vaccines according to medical need.
  • Medigene holds a patent in the US, Australia and Europe for the manufacturing of mature dendritic cells. The patent protects our process to generate polarized mature dendritic cells using our unique maturation cocktail.

Specific characteristics of Medigene’s new generation DC vaccines:

  • Medigene’s DCs display a surface profile composed of high levels of molecules needed for co-stimulation of T cells, leading to optimal activation.
  • DCs manufactured following Medigene’s protocol produce bioactive IL-12, a critical cytokine that is needed for effective activation of anti-tumor immunity.
  • Medigene’s DCs can also activate natural killer cells of the innate immune system to provide immune synergy of the innate and adaptive immune systems.

Personalized cancer treatment with DC vaccines

Isolation of DC precursor cells from patient's blood.

Tumor

Generation of dendritic cells and loading with tumor-associated antigens.

HLA complex
Tumor-associated antigen

New generation of DC vaccines loaded with tumor-associated antigens.

HLA-peptide complex

Freezing of vaccine cells in multiple aliquots.

Batch quality testing and vaccination according to protocol over defined time period.

Activation of tumor-specific patient-T cells by DCs. T cells seek and attack tumor cells.

Tumor
T cell
DC vaccine

Profile and function of dendritic cells

DCs were first recognized by Paul Langerhans in the late 19th century, and more fully characterized from 1973 onwards as a new immune cell that plays a crucial role in bridging innate and adaptive immunity. DCs are the most potent antigen-presenting cells that take up, process and present antigenic peptide fragments on their surface in conjunction with HLA molecules in a form that can induce antigen-specific T cells to mature and proliferate. In this way, T cells can recognize and eliminate tumor cells that bear the same antigen peptide on their surface. 

Click on the picture to see a short video of Medigene's DC vaccine technology